April 15, 2020 / 6:50 PM / 4 months ago

BRIEF-Roivant Doses First Patient In Trial Evaluating Gimsilumab In Covid-19 Patients For Treatment Of ARDS

April 15 (Reuters) - Roivant:

* ROIVANT DOSES FIRST PATIENT IN PIVOTAL BREATHE CLINICAL TRIAL EVALUATING GIMSILUMAB IN COVID-19 PATIENTS FOR THE PREVENTION AND TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME

* ROIVANT - FDA HAS AGREED THAT BREATHE CLINICAL TRIAL COULD SUPPORT REGISTRATION IF SUCCESSFUL

* ROIVANT - BREATHE IS AN ADAPTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL EXPECTED TO ENROLL UP TO 270 PATIENTS Source text for Eikon:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below